MGC Pharmaceuticals Probability of Future OTC Stock Price Finishing Over 0.21
| MGCLFDelisted Stock | USD 0.21 0.00 0.00% |
MGC |
MGC Pharmaceuticals Target Price Odds to finish over 0.21
The tendency of MGC OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.21 | 90 days | 0.21 | about 91.32 |
Based on a normal probability distribution, the odds of MGC Pharmaceuticals to move above the current price in 90 days from now is about 91.32 (This MGC Pharmaceuticals probability density function shows the probability of MGC OTC Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon MGC Pharmaceuticals has a beta of -0.94. This indicates Additionally MGC Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. MGC Pharmaceuticals Price Density |
| Price |
Predictive Modules for MGC Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as MGC Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.MGC Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. MGC Pharmaceuticals is not an exception. The market had few large corrections towards the MGC Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold MGC Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of MGC Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.3 | |
β | Beta against Dow Jones | -0.94 | |
σ | Overall volatility | 0.03 | |
Ir | Information ratio | -0.15 |
MGC Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of MGC Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for MGC Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| MGC Pharmaceuticals is not yet fully synchronised with the market data | |
| MGC Pharmaceuticals has some characteristics of a very speculative penny stock | |
| MGC Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| MGC Pharmaceuticals has accumulated 4.35 M in total debt with debt to equity ratio (D/E) of 0.84, which is about average as compared to similar companies. MGC Pharmaceuticals has a current ratio of 0.82, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist MGC Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, MGC Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MGC Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MGC to invest in growth at high rates of return. When we think about MGC Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 4.65 M. Net Loss for the year was (20.35 M) with profit before overhead, payroll, taxes, and interest of 562.87 K. | |
| MGC Pharmaceuticals has accumulated about 1.89 M in cash with (12.16 M) of positive cash flow from operations. |
MGC Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of MGC OTC Stock often depends not only on the future outlook of the current and potential MGC Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. MGC Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.6 B |
MGC Pharmaceuticals Technical Analysis
MGC Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. MGC OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of MGC Pharmaceuticals. In general, you should focus on analyzing MGC OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
MGC Pharmaceuticals Predictive Forecast Models
MGC Pharmaceuticals' time-series forecasting models is one of many MGC Pharmaceuticals' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary MGC Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about MGC Pharmaceuticals
Checking the ongoing alerts about MGC Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for MGC Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| MGC Pharmaceuticals is not yet fully synchronised with the market data | |
| MGC Pharmaceuticals has some characteristics of a very speculative penny stock | |
| MGC Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| MGC Pharmaceuticals has accumulated 4.35 M in total debt with debt to equity ratio (D/E) of 0.84, which is about average as compared to similar companies. MGC Pharmaceuticals has a current ratio of 0.82, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist MGC Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, MGC Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MGC Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MGC to invest in growth at high rates of return. When we think about MGC Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 4.65 M. Net Loss for the year was (20.35 M) with profit before overhead, payroll, taxes, and interest of 562.87 K. | |
| MGC Pharmaceuticals has accumulated about 1.89 M in cash with (12.16 M) of positive cash flow from operations. |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in MGC OTC Stock
If you are still planning to invest in MGC Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MGC Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |